By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
EU calls on Western Balkans to step up reforms for membership - 2Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- 3NASA’s history-making moon mission aims to send the first woman and person of color to deep space
- 4Why doing good also makes us feel good, during the holidays and beyond
- 5Solar storms can trigger auroras on Earth. This star’s explosion could destroy a planet’s atmosphere
- All that You Really want to Be familiar with Dental Inserts Facilities
- Gen Z workplace stereotypes were TV’s favorite punchline in 2025
- Pulsars to the extreme: Spinning dead stars found blasting radio signals from the 'edge of their magnetic reach'
- Artemis II live updates: NASA's moon mission breaks Apollo record for farthest distance humans have traveled from Earth
- NASA releases stunning first images of Earth taken by the Artemis II astronauts
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Canada Awards C$1.5 Billion Defense Contracts to L3Harris, Airbus
- Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- Attacks on Iran's Bushehr nuclear plant and on Iraq border crossing
